Reset Map5 Results
Rua do Campo Alegre 823 Porto, Porto, 1450-180 PortugalFairJourney Bio (FJBio) is a leading antibody discovery and engineering CRO supporting biotech and pharmaceutical companies in the discovery and development of next-generation therapeutic antibodies and biologics. FJBio provides integrated end-to-end solutions from target validation to optimized development candidate, combining advanced discovery technologies with deep expertise in antibody engineering, developability and functional characterization. Antibody Discovery Platforms Our discovery capabilities combine multiple complementary technologies to maximize success rates: Phage display antibody libraries (human, synthetic and immune repertoires) Single B-cell antibody discovery from human donors, immunized animals and transgenic platforms Hybridoma antibody generation Nanobody (VHH) discovery from llama immune libraries These platforms enable rapid identification of high-affinity binders across multiple antibody formats including IgG, Fab, scFv, VHH and engineered antibody fragments. Antibody Engineering & Optimization FJBio provides advanced antibody engineering services to optimize lead candidates for therapeutic development: affinity maturation and CDR engineering antibody humanization sequence optimization and developability improvement bispecific and multispecific antibody engineering antibody format conversion and optimization Biophysical Characterization & Developability Our comprehensive characterization capabilities ensure robust candidate selection and early risk mitigation: SPR kinetics and affinity measurement epitope binning and epitope mapping stability and aggregation analysis glycan profiling and HPLC analytics hydrophobicity, polyreactivity and developability screening Functional Assays FJBio provides a broad portfolio of cell-based and functional assays to evaluate antibody mechanism of action: receptor binding and blocking assays internalization assays reporter gene assays immune effector function analysis including ADCC, ADCP and CDC Antibody Production & Expression We offer flexible recombinant antibody expression and production capabilities including: mammalian expression systems bacterial expression systems antibody fragment production scalable antibody production for discovery and preclinical research Structural Biology & AI-Driven Antibody Design FJBio combines experimental platforms with advanced computational capabilities including: cryo-EM structural biology for antibody–antigen complex analysis rational antibody engineering supported by machine learning-driven sequence analysis Proven Track Record With more than 250 industry partners, over 1,400 projects completed and more than 19 antibodies advanced to clinical development or market, FJBio has established itself as a trusted scientific partner for antibody discovery programs worldwide. Our collaborative science-driven approach, combined with flexible discovery platforms and integrated characterization capabilities, enables partners to accelerate biologics discovery while reducing development risk. For more information, please visit: www.fjbio.com/
82B High Street, Sawston, Cambs, CB22 3HJ United KingdomFairJourney Bio (FJBio) is a leading antibody discovery and engineering CRO supporting biotech and pharmaceutical companies in the discovery and development of next-generation therapeutic antibodies and biologics. FJBio provides integrated end-to-end solutions from target validation to optimized development candidate, combining advanced discovery technologies with deep expertise in antibody engineering, developability and functional characterization. Antibody Discovery Platforms Our discovery capabilities combine multiple complementary technologies to maximize success rates: Phage display antibody libraries (human, synthetic and immune repertoires) Single B-cell antibody discovery from human donors, immunized animals and transgenic platforms Hybridoma antibody generation Nanobody (VHH) discovery from llama immune libraries These platforms enable rapid identification of high-affinity binders across multiple antibody formats including IgG, Fab, scFv, VHH and engineered antibody fragments. Antibody Engineering & Optimization FJBio provides advanced antibody engineering services to optimize lead candidates for therapeutic development: affinity maturation and CDR engineering antibody humanization sequence optimization and developability improvement bispecific and multispecific antibody engineering antibody format conversion and optimization Biophysical Characterization & Developability Our comprehensive characterization capabilities ensure robust candidate selection and early risk mitigation: SPR kinetics and affinity measurement epitope binning and epitope mapping stability and aggregation analysis glycan profiling and HPLC analytics hydrophobicity, polyreactivity and developability screening Functional Assays FJBio provides a broad portfolio of cell-based and functional assays to evaluate antibody mechanism of action: receptor binding and blocking assays internalization assays reporter gene assays immune effector function analysis including ADCC, ADCP and CDC Antibody Production & Expression We offer flexible recombinant antibody expression and production capabilities including: mammalian expression systems bacterial expression systems antibody fragment production scalable antibody production for discovery and preclinical research Structural Biology & AI-Driven Antibody Design FJBio combines experimental platforms with advanced computational capabilities including: cryo-EM structural biology for antibody–antigen complex analysis rational antibody engineering supported by machine learning-driven sequence analysis Proven Track Record With more than 250 industry partners, over 1,400 projects completed and more than 19 antibodies advanced to clinical development or market, FJBio has established itself as a trusted scientific partner for antibody discovery programs worldwide. Our collaborative science-driven approach, combined with flexible discovery platforms and integrated characterization capabilities, enables partners to accelerate biologics discovery while reducing development risk. For more information, please visit: www.fjbio.com/
Unit 2 London Road Cambridge, CB22 3EG United KingdomFairJourney Bio (FJBio) is a leading antibody discovery and engineering CRO supporting biotech and pharmaceutical companies in the discovery and development of next-generation therapeutic antibodies and biologics. FJBio provides integrated end-to-end solutions from target validation to optimized development candidate, combining advanced discovery technologies with deep expertise in antibody engineering, developability and functional characterization. Antibody Discovery Platforms Our discovery capabilities combine multiple complementary technologies to maximize success rates: Phage display antibody libraries (human, synthetic and immune repertoires) Single B-cell antibody discovery from human donors, immunized animals and transgenic platforms Hybridoma antibody generation Nanobody (VHH) discovery from llama immune libraries These platforms enable rapid identification of high-affinity binders across multiple antibody formats including IgG, Fab, scFv, VHH and engineered antibody fragments. Antibody Engineering & Optimization FJBio provides advanced antibody engineering services to optimize lead candidates for therapeutic development: affinity maturation and CDR engineering antibody humanization sequence optimization and developability improvement bispecific and multispecific antibody engineering antibody format conversion and optimization Biophysical Characterization & Developability Our comprehensive characterization capabilities ensure robust candidate selection and early risk mitigation: SPR kinetics and affinity measurement epitope binning and epitope mapping stability and aggregation analysis glycan profiling and HPLC analytics hydrophobicity, polyreactivity and developability screening Functional Assays FJBio provides a broad portfolio of cell-based and functional assays to evaluate antibody mechanism of action: receptor binding and blocking assays internalization assays reporter gene assays immune effector function analysis including ADCC, ADCP and CDC Antibody Production & Expression We offer flexible recombinant antibody expression and production capabilities including: mammalian expression systems bacterial expression systems antibody fragment production scalable antibody production for discovery and preclinical research Structural Biology & AI-Driven Antibody Design FJBio combines experimental platforms with advanced computational capabilities including: cryo-EM structural biology for antibody–antigen complex analysis rational antibody engineering supported by machine learning-driven sequence analysis Proven Track Record With more than 250 industry partners, over 1,400 projects completed and more than 19 antibodies advanced to clinical development or market, FJBio has established itself as a trusted scientific partner for antibody discovery programs worldwide. Our collaborative science-driven approach, combined with flexible discovery platforms and integrated characterization capabilities, enables partners to accelerate biologics discovery while reducing development risk. For more information, please visit: www.fjbio.com/
201 Gateway Blvd South San Francisco, CA, 94080 9823 United StatesFairJourney Bio (FJBio) is a leading antibody discovery and engineering CRO supporting biotech and pharmaceutical companies in the discovery and development of next-generation therapeutic antibodies and biologics. FJBio provides integrated end-to-end solutions from target validation to optimized development candidate, combining advanced discovery technologies with deep expertise in antibody engineering, developability and functional characterization. Antibody Discovery Platforms Our discovery capabilities combine multiple complementary technologies to maximize success rates: Phage display antibody libraries (human, synthetic and immune repertoires) Single B-cell antibody discovery from human donors, immunized animals and transgenic platforms Hybridoma antibody generation Nanobody (VHH) discovery from llama immune libraries These platforms enable rapid identification of high-affinity binders across multiple antibody formats including IgG, Fab, scFv, VHH and engineered antibody fragments. Antibody Engineering & Optimization FJBio provides advanced antibody engineering services to optimize lead candidates for therapeutic development: affinity maturation and CDR engineering antibody humanization sequence optimization and developability improvement bispecific and multispecific antibody engineering antibody format conversion and optimization Biophysical Characterization & Developability Our comprehensive characterization capabilities ensure robust candidate selection and early risk mitigation: SPR kinetics and affinity measurement epitope binning and epitope mapping stability and aggregation analysis glycan profiling and HPLC analytics hydrophobicity, polyreactivity and developability screening Functional Assays FJBio provides a broad portfolio of cell-based and functional assays to evaluate antibody mechanism of action: receptor binding and blocking assays internalization assays reporter gene assays immune effector function analysis including ADCC, ADCP and CDC Antibody Production & Expression We offer flexible recombinant antibody expression and production capabilities including: mammalian expression systems bacterial expression systems antibody fragment production scalable antibody production for discovery and preclinical research Structural Biology & AI-Driven Antibody Design FJBio combines experimental platforms with advanced computational capabilities including: cryo-EM structural biology for antibody–antigen complex analysis rational antibody engineering supported by machine learning-driven sequence analysis Proven Track Record With more than 250 industry partners, over 1,400 projects completed and more than 19 antibodies advanced to clinical development or market, FJBio has established itself as a trusted scientific partner for antibody discovery programs worldwide. Our collaborative science-driven approach, combined with flexible discovery platforms and integrated characterization capabilities, enables partners to accelerate biologics discovery while reducing development risk. For more information, please visit: www.fjbio.com/
Rua de Delfim Ferreira, 760 Porto, Porto, 4100-199 PortugalFairJourney Bio (FJBio) is a leading antibody discovery and engineering CRO supporting biotech and pharmaceutical companies in the discovery and development of next-generation therapeutic antibodies and biologics. FJBio provides integrated end-to-end solutions from target validation to optimized development candidate, combining advanced discovery technologies with deep expertise in antibody engineering, developability and functional characterization. Antibody Discovery Platforms Our discovery capabilities combine multiple complementary technologies to maximize success rates: Phage display antibody libraries (human, synthetic and immune repertoires) Single B-cell antibody discovery from human donors, immunized animals and transgenic platforms Hybridoma antibody generation Nanobody (VHH) discovery from llama immune libraries These platforms enable rapid identification of high-affinity binders across multiple antibody formats including IgG, Fab, scFv, VHH and engineered antibody fragments. Antibody Engineering & Optimization FJBio provides advanced antibody engineering services to optimize lead candidates for therapeutic development: affinity maturation and CDR engineering antibody humanization sequence optimization and developability improvement bispecific and multispecific antibody engineering antibody format conversion and optimization Biophysical Characterization & Developability Our comprehensive characterization capabilities ensure robust candidate selection and early risk mitigation: SPR kinetics and affinity measurement epitope binning and epitope mapping stability and aggregation analysis glycan profiling and HPLC analytics hydrophobicity, polyreactivity and developability screening Functional Assays FJBio provides a broad portfolio of cell-based and functional assays to evaluate antibody mechanism of action: receptor binding and blocking assays internalization assays reporter gene assays immune effector function analysis including ADCC, ADCP and CDC Antibody Production & Expression We offer flexible recombinant antibody expression and production capabilities including: mammalian expression systems bacterial expression systems antibody fragment production scalable antibody production for discovery and preclinical research Structural Biology & AI-Driven Antibody Design FJBio combines experimental platforms with advanced computational capabilities including: cryo-EM structural biology for antibody–antigen complex analysis rational antibody engineering supported by machine learning-driven sequence analysis Proven Track Record With more than 250 industry partners, over 1,400 projects completed and more than 19 antibodies advanced to clinical development or market, FJBio has established itself as a trusted scientific partner for antibody discovery programs worldwide. Our collaborative science-driven approach, combined with flexible discovery platforms and integrated characterization capabilities, enables partners to accelerate biologics discovery while reducing development risk. For more information, please visit: www.fjbio.com/
Site Information
The Contract Research Map is owned and maintained by Scientist.com. It was created to help researchers in the life sciences identify and connect with contract research organizations (CROs) based on geography. Updated nightly, this map features all of the available CROs within our network, so you can order services with a few clicks. Click on a specific country, scroll on the map itself or type into the search bar at the top—there are many ways to find the location and suppliers that you’re looking for. From Argentina to New Zealand, use this map to connect with a CRO near you.
We believe that every researcher across the world should be able to connect with the thousands of global CROs that exist and have the opportunity to work together. Like many industries,the life science supply chain has been disrupted over the last year. But there are many other circumstances such as international customs regulations or sensitive shipping times that create limitations around which countries are feasible to partner with. Sometimes, finding a CRO based in a country that best suits your research needs is imperative. We hope this contract research map allows you to find the right partner in the right place at the right time.
Have questions or feedback? We’d love to help. You can find our FAQs and contact information on the Learn more page.
Interested in connecting with one or more of the contract research organizations listed on this map? By clicking on the company’s name, you will be directed to their supplier profile on the Scientist.com marketplace. Once you set up a marketplace account you can start the ordering process immediately.
What is Scientist.com?
Scientist.com is the world's largest enterprise marketplace for outsourced R&D services. It saves time and money and provides access to innovation while maintaining compliance with an organization’s procurement policies.
How can I use Scientist.com?
Scientist.com has built private, enterprise marketplaces from 24 of the 30 largest pharmaceutical companies, 80+ biotech companies, the US National Institutes of Health (NIH) and numerous other pharma and biotech companies. If you are employed by one of these organizations, you can log in to get started today. If you are unsure about how to get started, you can email our team at support@scientist.com or go to our website www.scientist.comto speak to someone via our live chat.
Why should I place my order through Scientist.com?
Scientist.com is a highly efficient enterprise-wide outsourcing marketplace that makes it possible for research organizations to save time and money, access innovation and ensure compliance. It utilizes a universal legal agreement and AI technologies to enable research like never before. See how comparing proposals and getting 1-on-1 support from our Research Concierge® team will enable you to place more research today.
How do I get my organization listed on the map?
If your CRO isn’t showing up on the map, then please be sure your company profile is up to date in Scientist.com’s Backoffice. After logging in, click the Your Company button in the navigation at the top, and then select the Locations tab.
Information about my organization is incorrect, how do I fix it?
Head over to backoffice.scientist.com to update your supplier profile and information. It may take up to two business days for the updates to be reflected on the map.